Alejandro Lemor Ferrand, MD
Interventional Cardiology · Jackson, MSNPI 1295120673
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abiomed accounts for 73.8% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $18,841 and has fallen 71.8% since, to $5,316 in 2025.
Across 335 payments — averaging $109.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$27K
- Shockwave Medical, Inc$4K
- Teleflex LLC$639
- Livanova USA, Inc.$598
- Boston Scientific$487
- Inari Medical, Inc.$349
- plus $3K from 28 others
Across 2 payments — averaging $11,709 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$23K
What the payments were for
- Consulting fees$1,1003%
- Speaking & faculty fees$21,85060%
- Travel & lodging$1,6244%
- Food & beverage$12,01733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 174 | $27,014 |
| Shockwave Medical, Inc | 11 | $4,416 |
| Teleflex LLC | 5 | $639 |
| Livanova USA, Inc. | 9 | $598 |
| Boston Scientific | 4 | $487 |
| Inari Medical, Inc. | 26 | $349 |
| Philips North America LLC | 4 | $332 |
| Stryker | 7 | $265 |
| Boehringer Ingelheim | 7 | $256 |
| Penumbra, Inc. | 2 | $218 |
| Medtronic | 5 | $198 |
| AstraZeneca | 3 | $187 |
| Alnylam Pharmaceuticals Inc. | 5 | $164 |
| Pfizer | 8 | $136 |
| E.r. Squibb & Sons, L.L.C. | 8 | $129 |
| Bayer | 7 | $128 |
| Cardiva Medical, Inc. | 6 | $114 |
| Amgen | 8 | $108 |
| Impulse Dynamics (USA) Inc. | 5 | $104 |
| Edwards Lifesciences | 3 | $93 |
| Cordis US CORP. | 2 | $92 |
| Merck | 5 | $78 |
| Procyrion, Inc. | 2 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $55 |
| Angiodynamics, Inc. | 1 | $53 |
| Imperative Care, Inc | 2 | $53 |
| Abbott | 2 | $49 |
| Bridgebio Pharma, Inc. | 2 | $41 |
| Terumo Medical Corporation | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,591 in reported general payments places this provider in the 85th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 109 | $101,977 |
| EliquisApixaban | 79 | $54,592 |
| JardianceEmpagliflozin | 44 | $39,212 |
| FarxigaDapagliflozin Propanediol | 45 | $39,039 |
| Repatha SureclickEvolocumab | 38 | $32,465 |
| BrilintaTicagrelor | 21 | $9,766 |
| Metoprolol Succinate | 221 | $2,883 |
| Ezetimibe | 122 | $2,018 |
| Nifedipine ErNifedipine | 98 | $1,820 |
| Atorvastatin Calcium | 234 | $1,711 |
| Spironolactone | 104 | $1,097 |
| Rosuvastatin Calcium | 55 | $828 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 73 | $657 |
| Amlodipine Besylate | 104 | $604 |
| Carvedilol | 124 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $54,59279 claims |
| AstraZenecaFarxiga, Brilinta | $187 | $48,80566 claims |
| Boehringer IngelheimJardiance | $256 | $39,21244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Jackson
- John WinscottJackson$482K
- William CrowderJackson$331K
- James BennettJackson$160K
- Brett BennettJackson$126K
- David YoungJackson$28K
- Richard GuynesJackson$26K
- William NicholsJackson$25K
- Catherine LoweJackson$21K
- Jeremy WhiteJackson$18K
- Kellan AshleyJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.